
CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeutics Manufactured at the Point-of-Care

- CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing
- The goal is to provide a proof of concept for point-of-care manufacturing to reduce vein-to-vein time, decrease manufacturing costs, and minimize complex shipping logistics

Quote from Eytan Abraham, Head of Personalized Medicine, Lonza:

“We look forward to collaborating with CellPoint to accelerate and enable bringing novel cancer immunotherapies to the clinic and patients. The use of the Cocoon Platform, coupled with the array of CellPoints’ therapies and technologies, and Lonza’s manufacturing capabilities, will help to accelerate the path to the clinic and provide a smoother path to commercial approval. This collaboration also aims to illustrate the promise and feasibility of manufacturing autologous immunotherapies at the point-of-care by leveraging Cocoon’s unique platform capabilities.”

Quote from Tol Trimborn, Chief Executive Officer, CellPoint:

“CellPoint has selected Lonza’s Cocoon® Platform as the next-generation state-of-the-art closed and automated manufacturing device to develop its point-of-care strategy to make CAR-T affordable and more readily accessible. Over the past year, we have been working with Lonza to develop a manufacturing process that will allow a six to seven day vein-to-vein time to treat cancer patients.”

Leiden, Netherlands, Maryland, US and Basel, Switzerland, 23 June 2021 – CellPoint, a private, clinical-stage biopharmaceutical company developing novel platforms for gene-modified T-cells to treat cancers, and Lonza, a leading cell and gene therapy manufacturer, announced today that the companies have a cell therapy manufacturing agreement in place.

This collaboration, aimed at developing CellPoint’s T-cell therapies for treating various cancers, will leverage Lonza’s expertise in process development and its proprietary Cocoon® Platform. This automated and closed patient-scale cell therapy manufacturing platform offers flexibility

to execute a wide variety of protocols within a single system, which is enabled through a single-use, highly customizable cassette and custom programming.

Cell-based immunotherapies have been shown to be potent drugs that can treat multiple forms of incurable cancers. CellPoint has acquired various assets to develop CAR-T immunotherapies targeting hematological tumors and is intending to target solid tumors as well.

One of the key hurdles in making these therapies more accessible to larger patient populations is the difficulty in manufacturing these therapies at scale, robustly, and close to patients. CellPoint will utilize the Cocoon® Platform to manufacture cell therapies at the point-of-care, thereby lowering manufacturing costs, decreasing turnaround times to treatment, and minimizing complex logistics.

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. These enable our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 14,000 full-time employees, we are built from high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 4.5 billion in 2020 with a CORE EBITDA of CHF 1.4 billion. Find out more at www.lonza.com.

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

About CellPoint

CellPoint was founded in Leiden, The Netherlands in 2019 by industry veterans Maarten Zandvliet and Tol Trimborn. It is a seed-funded company (round led by +ND capital in 2020) and aims to initiate clinical trials of its proprietary CD19 CAR therapy later this year. BCMA CAR trials will follow early next year.

CellPoint is dedicated to developing CAR-T therapies at the point-of-care to treat patients with hematological malignancies to make these therapies more affordable and accessible to patients. CellPoint has developed a 6-day manufacturing process that allows for a 6-7 day vein-to-vein time compared to the over two weeks current industry standard.

Lonza Contact Details

Victoria Morgan

Head of External Communications
Lonza Group Ltd
Tel +41 61 316 2283
victoria.morgan@lonza.com

Dr. Martina Ribar Hesticová

Trade Media Lead
Lonza Group Ltd
Tel +41 61 316 8982
martina.ribarhesticova@lonza.com

Dirk Oehlers

Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540
dirk.oehlers@lonza.com

CellPoint Contact Details

Mary Clark, Manel Mateus, Stella Lempidaki

Optimum Strategic Communications
Tel: +44 (0) 203 922 0889
cellpoint@optimumcomms.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.